Protein Expression in Down Syndrome Brain
Editat de G. Lubecen Limba Engleză Hardback – 15 oct 2001
Preț: 1198.72 lei
Preț vechi: 1461.86 lei
-18%
Puncte Express: 1798
Carte tipărită la comandă
Livrare economică 11-25 august
Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
Specificații
ISBN-13: 9783211837320
ISBN-10: 3211837329
Pagini: 388
Ilustrații: X, 374 p.
Dimensiuni: 210 x 279 x 30 mm
Greutate: 1.29 kg
Ediția:2001
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
ISBN-10: 3211837329
Pagini: 388
Ilustrații: X, 374 p.
Dimensiuni: 210 x 279 x 30 mm
Greutate: 1.29 kg
Ediția:2001
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
Public țintă
ResearchCuprins
Decreased alpha-endosulfine, an endogenous regulator of ATP-sensitive potassium channels, in brains from adult Down syndrome patients.- Developmental instability of the cerebellum and its relevance to Down syndrome.- Expression of the multidrug resistance P glycoprotein (Pgp) and multidrug resistance associated protein (MRP1) in Down syndrome brains.- Deterioration of the transcriptional, splicing and elongation machinery in brain of fetal Down Syndrome.- Fetal life in Down Syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure.- Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome.- Glial-neurotrophic mechanisms in Down syndrome.- Aberrant expression of dihy-dropyrimidinase related proteins-2, -3 and -4 in fetal Down Syndrome brain.- Decreased protein levels of complex I 30-kDa subunit in fetal Down Syndrome brains.- Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome.- Functional genomics of Down Syndrome: a multidisciplinary approach.- Unaltered expression of Fas (CD95/APO-1), Caspase-3, Bcl-2 and Annexins in brain of fetal Down syndrome: evidence against increased apoptosis.- Alteration of caspases and other apoptosis regulatory proteins in Down syndrome.- Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-kB in brains of patients with Down syndrome.- Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down Syndrome and Alzheimer’s disease.- Carbohydrate handling enzymes in fetal Down Syndrome brain.- Changes in nicotinic acetylcholine receptor subunits expression in brain of patients withDown syndrome and Alzheimer’s disease.- Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down Syndrome.- Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome.- The brain in Down syndrome.- Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer’s disease.- Increased protein levels of heterogeneous nuclear ribonucleoprotein A2/B1 in fetal Down syndrome brains.- Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer’s disease.- Molecular neuropathology of transgenic mouse models of Down syndrome.- Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation.- Expression profiles of proteins in fetal brain with Down syndrome.- Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down Syndrome: dysregulation of T-complex protein 1.- ß-Amyliod precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect.- Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down Syndrome brain.- Alteration of gene expression in Down’s syndrome (DS) brains: its significance in neurodegeneration.